A national standard for evaluating antibacterial textiles, in effect for nearly two decades, is undergoing systemic revision. In June 2025, the task to revise 'Textiles - Evaluation of Antibacterial Activity - Part 2: Absorption Method' was officially assigned, followed by a review meeting in Zhejiang. This signals that the old GB/T 20944.2-2007 testing logic will soon be replaced. For the hundreds of millions of antibacterial socks, underwear, home textiles, and medical textiles flowing into the market each year, this standard update is not merely a technical document change—it triggers adjustments in testing costs, marketing claims, and procurement acceptance rules.
Revision Pace and Industry Context
The revision of antibacterial textile standards is not an isolated move but a coordinated update of the three-part series. The revision task for Part 3 (Shake Flask Method) was assigned in June 2024, and that standard has now completed revision and entered the approval stage, fully replacing GB/T 20944.3-2008. Part 2 (Absorption Method) was initiated in June 2025, and the review meeting marks progress from drafting toward consensus. While Part 1 (Agar Disc Diffusion Method) was not mentioned in the latest update, the series revision is clearly advancing in a coordinated rhythm.
Over the past two decades, antibacterial technology has penetrated the textile industry far faster than standard setters anticipated. From initial applications in underwear and socks, antibacterial features have become a key differentiator in sportswear, medical textiles, and home furnishings. Meanwhile, the large-scale application of new materials such as nano-silver, chitosan, and photocatalysts, along with improved testing instruments, has made old test methods and scopes inadequate. The direct consequence of outdated standards is that some companies exploit testing gaps for concept marketing, while buyers struggle to verify product authenticity under a unified benchmark.
Transmission Effects Across the Value Chain
The most immediate impact of the standard revision falls on testing. The absorption method, which evaluates antibacterial efficacy under simulated sweat or body fluid conditions, will change result comparability through adjustments in strain selection, culture conditions, and neutralization steps. For testing laboratories, this entails comprehensive updates in equipment calibration, personnel training, and proficiency testing. For brands, new product submissions may require fresh data accumulation, and whether existing antibacterial claims can rely on old reports becomes an open question.
On the production side, the revised standard will more closely reflect real-world usage scenarios, forcing companies to optimize antibacterial finishing agents and process parameters. For instance, some antibacterial agents that performed well under the old method may fail under more stringent washing conditions, driving formulation upgrades. This technical transmission will gradually show up in costs—compliant companies face higher R&D and testing expenses, while low-cost, low-quality antibacterial producers will face greater market exit pressure.
From a market order perspective, a unified and scientific standard helps compress space for false claims. Previously, antibacterial performance was invisible, and consumers relied on corporate self-descriptions. After the new standard is implemented, authoritative test reports will become a hard requirement for functional labeling. This means buyers can more confidently require suppliers to provide test reports based on the new standard, reducing return risks caused by functional discrepancies.